De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways

Matrix Biology

Volumn 35, Issue , 2014, Pages 132-142

  Zeng Brouwers, Jinyang ^a   Beckmann, Janet ^a   Nastase, Madalina Viviana ^a   Iozzo, Renato V ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemoattractants; Danger signal; Extracellular matrix; Innate immunity; Macrophage; Toll like receptors

Indexed keywords

ALBUMIN; BIGLYCAN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; RANTES; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; CHEMOTACTIC FACTOR; MYD88 PROTEIN, MOUSE; PRIMER DNA; TICAM-1 PROTEIN, MOUSE; TOLL LIKE RECEPTOR; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; KIDNEY PARENCHYMA; LEUKOCYTE; LIVER CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; T LYMPHOCYTE; TISSUE REACTION; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; BLOOD; DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANALYSIS OF VARIANCE; ANIMALS; BIGLYCAN; BLOTTING, WESTERN; CHEMOTACTIC FACTORS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY; LEUKOCYTES; MICE; MICE, TRANSGENIC; MYELOID DIFFERENTIATION FACTOR 88; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTORS;

EID: 84901460534     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.12.003     Document Type: Article

References (46)

1. Adapala V.J., Ward M., Ajuwon K.M. Adipose tissue biglycan as a potential anti-inflammatory target of sodium salicylate in mice fed a high fat diet. J. Inflamm. (Lond) 2012, 9:15.
2. Amenta A.R., Creely H.E., Mercado M.L., Hagiwara H., McKechnie B.A., Lechner B.E., Rossi S.G., Wang Q., Owens R.T., Marrero E., Mei L., Hoch W., Young M.F., McQuillan D.J., Rotundo R.L., Fallon J.R. Biglycan is an extracellular MuSK binding protein important for synapse stability. J. Neurosci. 2012, 32:2324-2334.
3. Babelova A., Moreth K., Tsalastra-Greul W., Zeng-Brouwers J., Eickelberg O., Young M.F., Bruckner P., Pfeilschifter J., Schaefer R.M., Grone H.J., Schaefer L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009, 284:24035-24048.
4. Berendsen A.D., Fisher L.W., Kilts T.M., Owens R.T., Robey P.G., Gutkind J.S., Young M.F. Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17022-17027.
5. Bianco P., Fisher L.W., Young M.F., Termine J.D., Robey P.G. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J. Histochem. Cytochem. 1990, 38:1549-1563.
6. Bowe M.A., Mendis D.B., Fallon J.R. The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. J. Cell Biol. 2000, 148:801-810.
7. Chen X.D., Shi S., Xu T., Robey P.G., Young M.F. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J. Bone Miner. Res. 2002, 17:331-340.
8. Choi H.U., Johnson T.L., Pal S., Tang L.H., Rosenberg L., Neame P.J. Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography. J. Biol. Chem. 1989, 264:2876-2884.
9. De Filippo K., Henderson R.B., Laschinger M., Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol. 2008, 180:4308-4315.
10. de Kluijver J., Schrumpf J.A., Evertse C.E., Sont J.K., Roughley P.J., Rabe K.F., Hiemstra P.S., Mauad T., Sterk P.J. Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. Clin. Exp. Allergy 2005, 35:1361-1369.
11. Derbali H., Bosse Y., Cote N., Pibarot P., Audet A., Pepin A., Arsenault B., Couture C., Despres J.P., Mathieu P. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am. J. Pathol. 2010, 176:2638-2645.
12. Fisher L.W., Termine J.D., Dejter S.W., Whitson S.W., Yanagishita M., Kimura J.H., Hascall V.C., Kleinman H.K., Hassell J.R., Nilsson B. Proteoglycans of developing bone. J. Biol. Chem. 1983, 258:6588-6594.
13. Fisher L.W., Heegaard A.M., Vetter U., Vogel W., Just W., Termine J.D., Young M.F. Human biglycan gene. Putative promoter, intron-exon junctions, and chromosomal localization. J. Biol. Chem. 1991, 266:14371-14377.
14. Frey H., Schroeder N., Manon-Jensen T., Iozzo R.V., Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013, 280:2165-2179.
15. Iozzo R.V., Goldoni S., Berendsen A., Young M. Small leucine-rich proteoglycans. The Extracellular Matrix: An Overview 2011, 197-266. Springer, New York. R.P. Mecham (Ed.).
16. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., Prestwich G.D., Mascarenhas M.M., Garg H.G., Quinn D.A., Homer R.J., Goldstein D.R., Bucala R., Lee P.J., Medzhitov R., Noble P.W. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 2005, 11:1173-1179.
17. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
18. Kikuchi A., Tomoyasu H., Kido I., Takahashi K., Tanaka A., Nonaka I., Iwakami N., Kamo I. Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells. J. Neuroimmunol. 2000, 106:78-86.
19. Kitaya K., Yasuo T. Dermatan sulfate proteoglycan biglycan as a potential selectin L/CD44 ligand involved in selective recruitment of peripheral blood CD16(-) natural killer cells into human endometrium. J. Leukoc. Biol. 2009, 85:391-400.
20. Krensky A.M., Ahn Y.T. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat. Clin. Pract. Nephrol. 2007, 3:164-170.
21. McAleer J.P., Rossi R.J., Vella A.T. Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF. J. Immunol. 2009, 182:5322-5330.
22. Merline R., Schaefer R.M., Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal 2009, 3:323-335.
23. Merline R., Moreth K., Beckmann J., Nastase M.V., Zeng-Brouwers J., Tralhao J.G., Lemarchand P., Pfeilschifter J., Schaefer R.M., Iozzo R.V., Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 2011, 4:ra75.
24. Merline R., Nastase M., Iozzo R.V., Schaefer L. Small leucine-rich proteoglycans: multifunctional signaling effectors. Extracellular Matrix: Pathobiology and Signaling 2012, 185-196. DE GRUYTER, Berlin. N.K. Karamanos (Ed.).
25. Moreth K., Brodbeck R., Babelova A., Gretz N., Spieker T., Zeng-Brouwers J., Pfeilschifter J., Young M.F., Schaefer R.M., Schaefer L. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Invest. 2010, 120:4251-4272.
26. Moreth K., Iozzo R.V., Schaefer L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 2012, 11:2084-2091.
27. Nastase M.V., Young M.F., Schaefer L. Biglycan: a multivalent proteoglycan providing structure and signals. J. Histochem. Cytochem. 2012, 60:963-975.
28. Nikitovic D., Aggelidakis J., Young M.F., Iozzo R.V., Karamanos N.K., Tzanakakis G.N. The biology of small leucine-rich proteoglycans in bone pathophysiology. J. Biol. Chem. 2012, 287:33926-33933.
29. Parisuthiman D., Mochida Y., Duarte W.R., Yamauchi M. Biglycan modulates osteoblast differentiation and matrix mineralization. J. Bone Miner. Res. 2005, 20:1878-1886.
30. Popovic Z.V., Wang S., Papatriantafyllou M., Kaya Z., Porubsky S., Meisner M., Bonrouhi M., Burgdorf S., Young M.F., Schaefer L., Grone H.J. The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J. Immunol. 2011, 187:6217-6226.
31. Rafii M.S., Hagiwara H., Mercado M.L., Seo N.S., Xu T., Dugan T., Owens R.T., Hook M., McQuillan D.J., Young M.F., Fallon J.R. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J. Cell. Physiol. 2006, 209:439-447.
32. Roche J.K., Keepers T.R., Gross L.K., Seaner R.M., Obrig T.G. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation. Am. J. Pathol. 2007, 170:526-537.
33. Schaefer L., Iozzo R.V. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J. Biol. Chem. 2008, 283:21305-21309.
34. Schaefer L., Iozzo R.V. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr. Opin. Genet. Dev. 2012, 22:56-57.
35. Schaefer L., Schaefer R.M. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2010, 339:237-246.
36. Schaefer L., Grone H.J., Raslik I., Robenek H., Ugorcakova J., Budny S., Schaefer R.M., Kresse H. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int. 2000, 58:1557-1568.
37. Schaefer L., Raslik I., Grone H.J., Schonherr E., Macakova K., Ugorcakova J., Budny S., Schaefer R.M., Kresse H. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J. 2001, 15:559-561.
38. Schaefer L., Macakova K., Raslik I., Micegova M., Grone H.J., Schonherr E., Robenek H., Echtermeyer F.G., Grassel S., Bruckner P., Schaefer R.M., Iozzo R.V., Kresse H. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am. J. Pathol. 2002, 160:1181-1191.
39. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., Marsche G., Young M.F., Mihalik D., Gotte M., Malle E., Schaefer R.M., Grone H.J. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115:2223-2233.
40. Schall T.J., Bacon K., Toy K.J., Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347:669-671.
41. Sjoberg A.P., Manderson G.A., Morgelin M., Day A.J., Heinegard D., Blom A.M. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 2009, 46:830-839.
42. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2008, 294:F697-F701.
43. Westergren-Thorsson G., Hernnas J., Sarnstrand B., Oldberg A., Heinegard D., Malmstrom A. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J. Clin. Invest. 1993, 92:632-637.
44. Wu H., Chen G., Wyburn K.R., Yin J., Bertolino P., Eris J.M., Alexander S.I., Sharland A.F., Chadban S.J. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 2007, 117:2847-2859.
45. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., Bonadio J., Boskey A., Heegaard A.M., Sommer B., Satomura K., Dominguez P., Zhao C., Kulkarni A.B., Robey P.G., Young M.F. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 1998, 20:78-82.
46. Young M.F., Bi Y., Ameye L., Chen X.D. Biglycan knockout mice: new models for musculoskeletal diseases. Glycoconj. J. 2002, 19:257-262.